Although further studies are required to understand the function of this enzyme in breast cancer patients and its relation with HA metabolism, these results confirm the data observed in vitro and in silico, and indicate that the mechanisms in which UGDH is involved could be altered during breast cancer progression and treatment. Here, UGDH is linked to breast carcinoma.